Pham Quang Duy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pham Quang Duy has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Chi Dung Vu
Center of Endocrinology, Metabolism, Genetic/Genomics and Molecular Therapy, Vietnam National Children’s Hospital, 18/879 La Thanh, Dong Da, Hanoi 11512, Vietnam
2 shared publications - Ha Thu Nguyen
National Children's Hospital Hanoi Vietnam
2 shared publications - Khanh Ngoc Nguyen
National Children's Hospital Hanoi Vietnam
2 shared publications - Thi Bich Ngoc Can
Center of Endocrinology, Metabolism, Genetic/Genomics and Molecular Therapy, Vietnam National Children’s Hospital, 18/879 La Thanh, Dong Da, Hanoi 11512, Vietnam
2 shared publications Bui Phương Thao
National Children's Hospital Hanoi Vietnam
1 shared publicationBui Thi Huong
National Children's Hospital Hanoi Vietnam
1 shared publication
Latest Publications
- 13 November 2026
- Published by Wiley in Clinical Endocrinology
Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6–8 With Central Precocious Puberty
Background: Brain magnetic resonance imaging (MRI) is recommended for selected girls with central precocious puberty (CPP). Routine brain magnetic resonance imaging (MRI) in girls aged 6–8 years with central precocious puberty (CPP) remains clinically controversial. Neurological features may help identify girls at higher risk, but whether basal luteinizing hormone (LH), a routinely measured marker of hypothalamic–pituitary–gonadal axis activation, provides additional information beyond age at diagnosis remains uncertain. Methods: In this retrospective cross‐sectional study, 848 girls aged 6–8 years diagnosed with CPP underwent brain MRI at Vietnam National Children's Hospital between April 2021 and June 2026. Brain MRI findings were classified as clinically significant/pathological, uncertain/questionable significance, or incidental. Neurological characteristics were compared across the MRI categories. Logistic regression was used to identify factors associated with clinically significant MRI abnormalities. Sequential models evaluated whether basal LH provided additional information beyond age at diagnosis, with model fit and discrimination assessed using likelihood‐ratio tests, Akaike information criterion (AIC) and area under the receiver operating characteristic curve (AUC). Results: Any brain MRI abnormalities were identified in 86 girls (10.1%), including 30 (3.5%) with clinically significant central nervous system (CNS) lesions, 14 (1.7%) with questionable findings and 42 (5.0%) with incidental findings. Neurological symptoms, signs or previous CNS history were more frequent among girls with clinically significant abnormalities than among those with uncertain or incidental findings (30.0%, 7.1% and 4.8%, respectively; p = 0.012). Basal LH was independently associated with clinically significant MRI abnormalities (adjusted OR 1.30 per IU/L, 95% CI 1.14–1.47; p < 0.001. Adding basal LH to age at diagnosis significantly improved model fit (AIC 247.79 vs. 259.78; likelihood‐ratio p = 0.0002), although discrimination remained modest (AUC 0.654 vs. 0.550 for age alone, p = 0.055). Bone‐age advancement did not provide significant additional information. Conclusions: In girls aged 6–8 years with CPP, brain MRI abnormalities were identified in approximately 1 in 10 girls, but most were incidental or of uncertain clinical significance. Clinically significant abnormalities were enriched among girls with neurological features. Basal LH provided incremental information beyond age at diagnosis but had limited discriminatory performance. These findings support a risk‐stratified approach to brain MRI in girls aged 6–8 years with CPP, with careful neurological assessment remaining central to imaging decisions.
- 13 November 2026
- Published by Wiley in Clinical Endocrinology
Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6–8 With Central Precocious Puberty
Background: Brain magnetic resonance imaging (MRI) is recommended for selected girls with central precocious puberty (CPP). Routine brain magnetic resonance imaging (MRI) in girls aged 6–8 years with central precocious puberty (CPP) remains clinically controversial. Neurological features may help identify girls at higher risk, but whether basal luteinizing hormone (LH), a routinely measured marker of hypothalamic–pituitary–gonadal axis activation, provides additional information beyond age at diagnosis remains uncertain. Methods: In this retrospective cross‐sectional study, 848 girls aged 6–8 years diagnosed with CPP underwent brain MRI at Vietnam National Children's Hospital between April 2021 and June 2026. Brain MRI findings were classified as clinically significant/pathological, uncertain/questionable significance, or incidental. Neurological characteristics were compared across the MRI categories. Logistic regression was used to identify factors associated with clinically significant MRI abnormalities. Sequential models evaluated whether basal LH provided additional information beyond age at diagnosis, with model fit and discrimination assessed using likelihood‐ratio tests, Akaike information criterion (AIC) and area under the receiver operating characteristic curve (AUC). Results: Any brain MRI abnormalities were identified in 86 girls (10.1%), including 30 (3.5%) with clinically significant central nervous system (CNS) lesions, 14 (1.7%) with questionable findings and 42 (5.0%) with incidental findings. Neurological symptoms, signs or previous CNS history were more frequent among girls with clinically significant abnormalities than among those with uncertain or incidental findings (30.0%, 7.1% and 4.8%, respectively; p = 0.012). Basal LH was independently associated with clinically significant MRI abnormalities (adjusted OR 1.30 per IU/L, 95% CI 1.14–1.47; p < 0.001. Adding basal LH to age at diagnosis significantly improved model fit (AIC 247.79 vs. 259.78; likelihood‐ratio p = 0.0002), although discrimination remained modest (AUC 0.654 vs. 0.550 for age alone, p = 0.055). Bone‐age advancement did not provide significant additional information. Conclusions: In girls aged 6–8 years with CPP, brain MRI abnormalities were identified in approximately 1 in 10 girls, but most were incidental or of uncertain clinical significance. Clinically significant abnormalities were enriched among girls with neurological features. Basal LH provided incremental information beyond age at diagnosis but had limited discriminatory performance. These findings support a risk‐stratified approach to brain MRI in girls aged 6–8 years with CPP, with careful neurological assessment remaining central to imaging decisions.
- 1 October 2026
- Published by Wiley in Clinical Endocrinology
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency
Objective: Growth hormone deficiency (GHD) is an important cause of growth failure in children. Although recombinant human growth hormone (rhGH) promotes catch‐up growth, longitudinal differences in treatment response between isolated growth hormone deficiency (IGHD) and combined pituitary hormone deficiency (CPHD) remain unclear. This study compared longitudinal growth trajectories during rhGH therapy between IGHD and CPHD patients. Design and Patients: A retrospective cohort study included 72 IGHD and 48 CPHD patients. Measurements: Height standard deviation score (SDS) was assessed at baseline and after 12, 24, 36 and 48 months of rhGH therapy. Longitudinal trajectories were analysed using linear mixed‐effects models adjusted for age at treatment initiation, bone age, BMI SDS and pituitary MRI findings. Results: CPHD patients had more severe growth impairment at baseline than those with IGHD (height SDS: −5.00 ± 1.57 vs. −3.20 ± 1.12; p < 0.001). However, CPHD demonstrated greater catch‐up growth, achieving larger cumulative height SDS gains after 48 months (3.10 ± 1.36 vs. 1.92 ± 0.87 SDS; p < 0.001). Mixed‐effects modelling confirmed significantly different longitudinal growth trajectories (time‐by‐diagnosis interaction: χ 2 = 66.62, p < 0.001). Adjusted height SDS improved from −3.40 to −1.49 in IGHD and from −4.56 to −1.55 in CPHD. At 48 months, the adjusted CPHD–IGHD difference was −0.06 SDS (95% CI, −0.63 to 0.51), consistent with substantial convergence of the two growth trajectories. Older age at treatment initiation and abnormal pituitary MRI findings were independently associated with lower height SDS across follow‐up. Conclusions: Despite more severe baseline growth impairment, children with CPHD experienced greater catch‐up growth during rhGH therapy, resulting in substantial convergence of longitudinal height SDS trajectories toward those of children with IGHD over 4 years.
- 1 October 2026
- Published by Wiley in Clinical Endocrinology
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency
Objective: Growth hormone deficiency (GHD) is an important cause of growth failure in children. Although recombinant human growth hormone (rhGH) promotes catch‐up growth, longitudinal differences in treatment response between isolated growth hormone deficiency (IGHD) and combined pituitary hormone deficiency (CPHD) remain unclear. This study compared longitudinal growth trajectories during rhGH therapy between IGHD and CPHD patients. Design and Patients: A retrospective cohort study included 72 IGHD and 48 CPHD patients. Measurements: Height standard deviation score (SDS) was assessed at baseline and after 12, 24, 36 and 48 months of rhGH therapy. Longitudinal trajectories were analysed using linear mixed‐effects models adjusted for age at treatment initiation, bone age, BMI SDS and pituitary MRI findings. Results: CPHD patients had more severe growth impairment at baseline than those with IGHD (height SDS: −5.00 ± 1.57 vs. −3.20 ± 1.12; p < 0.001). However, CPHD demonstrated greater catch‐up growth, achieving larger cumulative height SDS gains after 48 months (3.10 ± 1.36 vs. 1.92 ± 0.87 SDS; p < 0.001). Mixed‐effects modelling confirmed significantly different longitudinal growth trajectories (time‐by‐diagnosis interaction: χ 2 = 66.62, p < 0.001). Adjusted height SDS improved from −3.40 to −1.49 in IGHD and from −4.56 to −1.55 in CPHD. At 48 months, the adjusted CPHD–IGHD difference was −0.06 SDS (95% CI, −0.63 to 0.51), consistent with substantial convergence of the two growth trajectories. Older age at treatment initiation and abnormal pituitary MRI findings were independently associated with lower height SDS across follow‐up. Conclusions: Despite more severe baseline growth impairment, children with CPHD experienced greater catch‐up growth during rhGH therapy, resulting in substantial convergence of longitudinal height SDS trajectories toward those of children with IGHD over 4 years.